Human lymphomas continue to represent a major challenge in oncology, and in particular occur at very high frequencies in AIDS patients. We report here the development of a CD30 þ lymphoproliferative disease in mice lacking the proapoptotic transcription factor, interferon regulatory factor-1. These mice most closely represent a model of human anaplastic large-cell lymphoma (ALCL). This mouse model of lymphoma will likely be useful in understanding the development of ALCL and in understanding the development of other closely related CD30 þ forms of lymphoma, such as CD30 þ Hodgkin's disease and CD30 þ cutaneous T-cell lymphoma. This mouse model will also be useful in testing therapies for different forms of CD30 þ lymphoma, in particular anti-CD30-based therapies.
Introduction
Interferon regulatory factor-1 (IRF-1) is a transcription factor that functions as a key regulator of innate and acquired immunity. It induces transcription of multiple genes required for host defense, including genes that effect the IFN-a/b-mediated response to viral pathogens Miyamoto et al., 1988; Matsuyama et al., 1993; Amakawa et al., 1996) ; the nitric oxide (NO) synthase gene (Smith et al., 1993; Martin et al., 1994; Salkowski et al., 1996; Spink and Evans, 1997) ; and cytokine (Matsuyama et al., 1993) and MHC class I and II Hobart et al., 1997) genes, which encode proteins that promote the activation of macrophage, natural killer cell-mediated cytotoxicity (Duncan et al., 1996; Ogasawara et al., 1998; Ohteki et al., 1998; Galon et al., 1999) , and the induction of the Th1 response (Taki et al., 1997) . IRF-1 expression is induced by a variety of factors: the type I interferons, interferonalpha and -beta (IFN-a/b) , type II interferon, interferon-gamma (IFN-g) (Briken et al., 1995; Blanar et al., 1989) , interleukin-12 (IL-12) (Galon et al., 1999) , IL-6 (Heinrich et al., 1998) , leukemia inhibitory factor (LIF), and tumor necrosis factor (TNF) (Ohmori and Hamilton, 1995) .
Studies of IRF-1À/À mice revealed that IRF-1 controls both positive and negative selection of CD8 þ thymocytes by regulating genes crucial for lineagespecific differentiation of CD8 þ cells (Penninger et al., 1997) . The severe reduction in the number of CD8 þ T cells in the IRF-1À/À mice is also attributable to the reduced expression of MHC class I, and MHC class Iassociated molecules, and the subsequent defect in maturation of MHC class I-restricted CD8 þ cells in the thymus (Matsuyama et al., 1993; Penninger et al., 1997) . Although maturation of CD4 þ cells occurs normally in IRF-1À/À mice, these mice have an increased memory/effector CD4 þ subset and a reduced naı¨ve cell subset. CD4 þ T cells from IRF-1À/À mice also have decreased levels of Th1 cytokines and increased levels of Th2 cytokines, demonstrating a role for IRF-1 in the homeostasis of T-cell subsets (McElligott et al., 1997) .
IRF-1 is also essential for DNA damage-induced apoptosis in T cells and growth arrest of murine embryonic fibroblasts (MEFs) (Tanaka et al., 1996) . Furthermore, studies have shown that IRF-1 functions as a tumor suppressor protein Willman et al., 1993) . IRF-1 reverses the transformed phenotype induced by IRF-2 overexpression , and mediates the resistance to cHA-Ras transformation, as determined by comparing the cHA-Ras transformation of IRF-1 expressing MEFs to IRF-1 null (IRF-1À/À) MEFs . Deletions and/or translocations involving one or both IRF-1 alleles are frequently observed in human cancers and are thought to play a role in tumorigenesis (Miura et al., 1992; Willman et al., 1993; Bartett et al., 1996; Ogasawara et al., 1996; Ransom et al., 1996; Sugimura et al., 1997; Zhao et al., 1997) . In addition, alternative splicing of IRF-1 mRNA, producing nonfunctional protein, occurs at high frequencies in patients with myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) . Loss of IRF-1 alone (IRF-1À/À) has not been previously shown to be associated with spontaneous tumor development in mice, but greatly increases tumor susceptibility in combination with tumor predispositions caused by cHa-Ras expression or p53 null zygosity (p53À/À) (Nozawa et al., 1999) . This increase in tumor formation, and data indicating that many tumors lacking the retinoblastoma tumor suppressor protein (Rb) have reduced IRF-1 (Eason and Blanck, 2001) expression, prompted our investigation to determine the effect of loss of IRF-1 in mice also lacking Rb (Jacks et al., 1992; Lee et al., 1992; Nikitin et al., 1999) .
Materials and methods

Animals
C57BL/6Rb þ /À mice (Jacks et al., 1992) were obtained from Jackson Laboratories (Bar Harbor, ME, USA) (C57Bl/6J-Rb1 tm1Tyj ). C57BL/6 IRF-1À/À mice were generated by crossbreeding IRF-1 þ /À breeding pairs kindly provided by Dr Tak Mak (Amgen Institute, Toronto, Canada) (Duncan et al., 1996) . The Rb þ /À IRF-1À/À and Rb þ /À IRF-1 þ / þ mice were produced from crosses between Rb þ /À and IRF-1À/À and subsequent backcrosses of the Rb þ /À IRF-1 þ /À offspring with the IRF-1À/À founder. Genotypes were confirmed on genomic DNA isolated from tail snips and amplified by PCR with the primer sets, as described by Jacks et al. (1992) for Rb and by Salkowski et al. (1996) for IRF-1.
Collection and morphological analysis of animal material
The mice were euthanized in a CO 2 chamber and examined macroscopically during necropsy. Representative samples of tissues were submitted for histologic examination. After fixation in 10% neutral buffered formalin for 6 h, the tissue samples were processed into paraffin blocks. Tissue sections (3-4 mm) were obtained from the paraffin blocks and stained with hematoxylin and eosin (H&E) (Richard-Allan Scientific, Kalamazoo, MI, USA) using standard histologic techniques.
Immunostaining
Tissue sections were subjected to immunostain for antibodies indicated in the figures using the avidin biotin peroxidase complex technique (Vectastatin Elite ABC Kit, Vector, Burlingame, CA, USA) at 2 Â concentration on the Dako Autostainer (Dako Corporation, Carpinteria, CA, USA). Antibodies were applied following microwave antigen retrieval (high to boiling, then 20 min at power level 5 in 0.01 citrate buffer, in a 100W Emerson Model AT736A microwave).
Electron microscopy
Lymphatic tissue samples with the adjacent tissue containing venules, arterioles and capillaries were fixed on ice, immediately after dissection, in a 2.5% glutaraldehyde-2.0% paraformaldehyde solution containing 0.1 m cacodylate buffer (pH 7.4). Samples were postfixed in cacodylate-buffered 1% OsO 4 for 2 h at 41C. After dehydration in graded alcohol, tissue pieces were embedded in a mixture of epon-araldite. Ultrathin sections were stained with uranyl acetate and lead citrate and were studied with the Hitachi H-7000 electron microscope in transmission mode.
Results
Lymphadenopathy in IRF-1À/À mice
Gross inspection and measurements of the lymph nodes retrieved from seven Rb þ /À IRF-1 þ / þ and ten Rb þ /À IRF-1À/À 330-day-old mice revealed a substantial increase in the size of all lymph nodes in 100% of Rb þ /À IRF-1À/À mice ( Table 1) . None of the Rb þ /À IRF-1 þ / þ mice had any indication of any enlarged or diseased lymph nodes. Microscopic examination of H&E stained lymph nodes revealed an abnormal architecture in the lymph nodes from the Rb þ /À IRF-1À/À mice, while that of the Rb þ /À IRF-1 þ / þ mice appeared normal ( Figure 1 ). Normal lymph nodes in the Rb þ /À IRF-1 þ / þ mice contained patent sinuses, a well-preserved cortical zone with an occasional small germinal center, and a heteromorphous paracortical and medullary zone containing a predominance of small mature-appearing lymphocytes. Mitoses were rare. The markedly enlarged lymph nodes from the Rb þ /À IRF-1À/À mice contained small cortical nodules and a diffuse expansion of the paracortical and medullary zones by a population of eosinophils, large cleaved lymphocytes, immunoblasts, histiocytes, and scattered small lymphocytes. Mitotic activity was increased, with as many as 2-3 mitoses per high power field ( Figure 2 ).
To determine whether the Rb defect played a role in the abnormal lymph nodes in the Rb þ /À IRF-1À/À Values were calculated from all recoverable lymph nodes from three mice for each indicated genotype. b Values were calculated from the largest 13 lymph nodes found in necropsies of three mice each representing the indicated genotypes mice, we compared the diameters of the lymph node of mice with two wild-type Rb alleles and lacking IRF-1 (Rb þ / þ IRF-1À/À) with the lymph nodes diameters of the Rb þ /À IRF-1À/À mice. While there appeared to be a trend towards larger lymph nodes in the Rb þ /À IRF-1À/À mice, there was no statistical difference in the lymph node diameters of the mice representing the two different genotypes. Furthermore, the same abnormal lymph node architecture and abnormal cell proliferation was apparent in the lymph nodes of mice lacking IRF-1 but having two wild-type Rb alleles (Figures 1 and 2) . Therefore, the observed lymphadenopathy and T-zone infiltrate correlated with the IRF-1À/À background.
We next determined that the total number of cells in lymph nodes from mice lacking IRF-1, at 330 days, was significantly greater than the number of cells in lymph nodes from normal mice, consistent with the increased size of the IRF-1À/À lymph nodes (Table 2) . Also, the percentage of nonlymphocytes was greater in the IRF-1À/À lymph nodes (Table 3) , as determined by flow cytometry analyses, consistent with the polymorphous nature of the paracortical zone in particular, revealed by the H&E stains (Figures 1 and 2) .
To assess the lineage of the large abnormal cells, and to further characterize the effect of loss of IRF-1 on the resulting abnormal architecture, the lymph nodes were stained with antibodies that recognize the T-cellspecific CD3, the T-cell/myeloid-associated CD43, the NK/T-cell-associated CD56, and the B-cell-specific CD20. Staining of the lymph nodes from the Rb þ /À IRF-1À/À mice with anti-CD3 and anti-CD43 revealed a background of small T cells positive for both antibodies, with no staining of the large atypical cells and immunoblasts (Figure 3 ). These cells were also negative for anti-CD56 (data not shown) and anti-CD20 (Figure 4) . Immunohistochemistry confirmed the lymph node effacement evident by H&E, and also confirmed the T-zone (paracortical and medullary) localization of this infiltrate. The lymph nodes from Rb þ /À IRF-1 þ / þ mice exhibited a normal distribution and localization of T cells (primarily interfollicular Previous studies showed that IRF-1À/À mice have a greatly reduced NK cell population (Duncan et al., 1996; Ogasawara et al., 1998; Ohteki et al., 1998; Galon et al., 1999) . CD56 staining of the lymph nodes indicated that virtually no CD56-positive NK cells were present in the Rb þ /À IRF-1À/À mice. The abnormal, large lymphoid cells (immunoblasts) were also CD56 negative (data not shown).
Examination of other tissues identified disseminated disease, with similar infiltrates noted in the lungs, spleen, skin, and focally in the gastrointestinal tract (data not shown). The pattern of infiltration in the spleen and lymph nodes was similar, with effacement and expansion of the T-cell-dependent regions. However, the sizes of the spleens could not be established, with a statistical significance, to be increased in all of the IRF-1À/À mice, unlike in the case of the lymph nodes. The lungs of IRF-1À/À mice showed extensive perivascular infiltrates composed of a heteromorphous lymphoid population similar to that noted in the spleen and lymph nodes ( Figure 5 ). There was angio-invasion. The infiltrate contained predominately CD3/CD43 þ T cells with admixed B cells (Figure 6 ), and occasional immunoblasts negative for CD3 and CD20.
Characterization of the abnormally proliferating IRF-1À/À immunoblasts
To further characterize the abnormal immunoblasts, we examined the lymph nodes by electron microscopy (EM), which clearly distinguished the immunoblasts from other large, apparently normal immune function cells, such as eosinophils and macrophages, admixed with numerous cell-types in the IRF-1À/À lymph nodes (Figure 7) . Furthermore, the EM analyses verified the low granularity of the immunoblast cytoplasm, noted in the H&E stain. The EM analyses also revealed immunoblast filapodia, characteristic of human lymphoma (Widgren, 1985) , in some cases interposed between apparently normal lymph node cells (Figure 7) .
The large size of the IRF-1À/À immunoblasts, the commonly observed kidney-shaped nuclei and the low-granularity cytoplasms are characteristics of the abnormal immunoblasts of anaplastic large-cell lymphoma (ALCL), which often express CD30 (Herbst et al., 1989; Falini, 2001) . Likewise, the IRF-1À/À immunoblasts in both the lymph nodes and in the disseminated infiltrates were CD30 þ (Figure 8 ). We have not been able to detect a single CD30 þ cell during extensive examinations of the lymph nodes of IRF-1 þ / þ mice.
All of the above data indicating abnormal lymphoid proliferation were obtained with mice about 330 days old. This assay period reflected the period required for development of the RbÀ/À tumors in Rb þ /À mice, a subject of the original experiment, as described above. The determination that the Rb þ /À genotype was not required for detection of the abnormal lymphoid proliferation raises the question of why a previous report (Nozawa et al., 1999) of assays for tumorigenesis in IRF-1À/À mice indicated that there was no hyperplasia in these mice. In the previous report, the mice were examined at 200 days (Nozawa et al., 1999) . To determine if it is possible to observe lymph node hyperplasia at 200 days, we measured the lymph nodes of 200-day-old IRF-1À/À mice, which had sizes similar to wild-type mice, that is, sizes that did not indicate any hyperplasia (Table 1) . We examined the lymph nodes of the 200-day-old IRF-1À/À mice with H&E, CD3 and CD20 stains and microscopic inspection. These analyses did not reveal any abnormal lymph node architecture ( Figure 9 ).
Basis for increased lymph node size in IRF-1À/À mice
Consistent with the increased size of the IRF-1À/À lymph nodes, and the increased number of mitoses observed in the H&E analyses (Figure 3) , we detected cells in the G2/M phase of the cell cycle, by propidium iodide staining and flow cytometry, in the lymph nodes from 330-day-old IRF-1À/À mice. We could not detect any G2/M phase cells in lymph nodes from wild-type or 200-day-old IRF-1À/À mice (Table 4) . (We have not been able to detect any consistent differences in apoptosis rates of the cells from the lymph nodes of the different mice in Table 4 .) 
Discussion
The data above indicate that lack of IRF-1 leads to abnormal proliferation of a CD30 þ immunoblast, consistent with other known effects of the lack of IRF-1, such as reduced apoptosis. No role for Rb was indicated by the experiments above; however, a role for the Rb pathway of growth control in development of the CD30 þ lymphoproliferative disease (LPD) in the IRF-1À/À mice has not been ruled out. In particular, defects in p16, which indirectly regulates Rb activity, are common in human lymphoma (Ogawa et al., 1995; Siebert et al., 1995; Uchida et al., 1995; Heyman et al., 1996; Kumanishi et al., 1996; Pinyol et al., 1997; Uchida et al., 1998; Baur et al., 1999; Moller et al., 2000) . On the other hand, very little is known about the function of the Rb growth control pathway in normal mouse lymphoid cells, and thus it is possible that this pathway is not relevant to the development of lymphoid-related tumors, particularly in mice. The results described above contrast with a previous study of p53À/À IRF-1À/À mice, where loss of IRF-1 was associated with a reduced incidence of lymphoma compared to the level observed in mice lacking only p53. No lymphomas were reported for IRF-1À/À mice (Nozawa et al., 1999) ; however, the mice examined above were significantly older than the mice described in the previous report (B 200 days old versus B 330 days old).
Mice lacking CD30 have enlarged thymuses and impaired negative selection of T cells (Amakawa et al., 1996) , consistent with CD30 as a member of the TNF family of cell surface receptors (Smith et al., 1993; Aizawa et al., 1997; Lee and Choi, 1997) and as a possible mediator of apoptosis (Gruss et al., 1994; Amakawa et al., 1996; Duckett and Thompson, 1997; Lee and Choi, 1997; Telford et al., 1997; Mir et al., 2000) . CD30 is also expressed on mitogen-activated (Hsu and Hsu, 1990; Bashir et al., 1992; Wendtner et al., 1995) and virally infected lymphocytes, such as HIV (Carbone et al., 1991; Gonzalez-Clemente et al., 1991; Chadburn et al., 1993; Nosari et al., 1996) and HTLV I infected T cells (Anagnostopoulos et al., 1990) . CD30 expression is apparently more strongly, though by no means exclusively, associated with the Th2 response (Del Prete et al., 1995a, b) , but there is no known role of CD30 expression specific to the Th2 response.
Constitutive CD30 expression occurs in at least five different types of lymphomas: (i) ALCL (Herbst et al., 1989) , (ii) Hodgkin's disease (HD) (Udayachander et al., 1983; Andreesen et al., 1984) , (iii) follicular lymphoma (FL) (Gardner et al., 2001) , (iv) diffuse large B-cell nonHodgkin's lymphoma (Gardner et al., 2001) , and (v) primary cutaneous T-cell lymphoma (CTLC). Both FL and diffuse large B-cell non-Hodgkin's lymphoma stain for both CD30 and B-cell markers, most importantly CD20. The CD30 þ cells in the IRF-1À/À mice are CD3 negative and CD20 negative (Figures 3 and 4) . Thus, these CD30 þ cells do not represent either FL or diffuse large B-cell non-Hodgkin's lymphoma. For this and other reasons, such as the characteristics of the effacement of the lymph node architecture seen in the IRF-1À/À lymph nodes, the IRF-1À/À mice do not represent a model for FL or diffuse large B-cell nonHodgkin's lymphoma.
Primary CTCL is almost always CD4 þ , but can be null for T markers. Also, CTCL can be a secondary clinical feature for systemic (i.e. nodal) ALCL. These mice also do not represent a model for primary CTCL, because mice lacking IRF-1 do not develop skin lesions, rashes or scaling, common to primary CTCL. (Foss et al., 1996; Marafioti et al., 2000; Falini, 2001) . Thus, in ALCL, the vast majority of CD30 þ null cells evince Tcell receptor (TcR) rearrangements, and in HD, the vast majority of CD30 þ null cells have a demonstrable Bcell receptor rearrangement.
Other characteristics also distinguish CD30 þ ALCL cells from CD30 þ HD cells. CD30 þ HD cells are Reed-Sternberg (RS) cells and are characterized by pale nuclei, accentric nucleoli, and the large cytoplasm (Chan, 2001) . The RS cells are also commonly multinucleated. The large cells of ALCL are characterized by lobulated nuclei, and ALCL lymph nodes have an admixture of large numbers of macrophages, neutrophils, and other cells. In both cases, fibrous regions of the lymph nodes can be detected. The diffuse infiltrative nature of the disease in the IRF-1À/À mice, in many tissues, the effacement of the normal nodal architecture, and increased mitotic activity are highly suggestive of a T-cell neoplasm (i.e. ALCL). The associated histiocytic, eosinophilic, and plasma cell infiltration, along with the background T lymphocytes and pattern of T-zone infiltration (see especially Figure 8 ) would also suggest a probable T-cell origin.
CD30 cross-linking and ligand (CD153) binding can lead to apoptosis in ALCL (Mir et al., 2000) , but not in HD (Hsu and Hsu, 2000) . CD30 signaling leads to NF-kB activation in HD, but not in ALCL (Mir et al., 2000; Horie et al., 2002) . The overall significance of CD30 function in the development of either ALCL or HD is unknown, but CD30 þ tumors are often accompanied by the presence of secreted CD30 in patient serum, consistent with the idea that in at least (Annunziata et al., 2000; Marafioti et al., 2000) .
The knowledge of the development of CD30 þ lymphoma in mice will provide an opportunity to test therapies designed to halt the development of this disease. Also, the IRF-1À/À mice will likely be useful in further understanding the underlying mechanisms of the development of CD30 þ lymphomas. For example, the CD30 þ lymphomas are common in patients with depressed immune states, and the IRF-1À/À mice have various immune function defects that may be contributing to the development of the disease. Also, a fusion protein involving nucleophosmin is very common in ALCL (Bischof et al., 1997; Bai et al., 2000; Kondo et al., 1997) , and nucleophosmin interacts with IRF-1. The observations reported here strongly support an investigation into the effects of the ALCL nucleophosmin fusion proteins on IRF-1 function in ALCL. 
